Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Rhythm Biosciences’ new clinical trial shows increases accuracy for their simple cancer blood test

  • In News
  • April 4, 2022
  • Samantha Freidin
Rhythm Biosciences’ new clinical trial shows increases accuracy for their simple cancer blood test

Colorectal cancer is the second leading cause of cancer-related death in Australia. This can be attributed to the silent nature of the disease, not causing symptoms until tumours are well established. 

The Australian Government is all too aware of this, having created the National Bowel Cancer Screening Program with the goal of early detection to circumvent preventable deaths. The Program sends testing kits to Australians on their 50th birthday, and encourages regular testing every few years from the ages of 50 to 74. 

Designed to detect blood in the stool, fecal occult blood tests (FOBTs) are the current standard of care for colorectal cancer detection. Definitive diagnosis is made with a colonoscopy which is highly invasive. 

Unfortunately the Government’s efforts aren’t as successful as they’d hoped, with only 43.5% of people returning their testing kits in 2018-2019. 

In an effort to combat this, diagnostic tech company Rhythm Biosciences (ASX: RHY) have developed a simple blood test designed to detect colorectal cancer. The ColoSTAT test is cost effective and minimally invasive, detecting biomarkers of colorectal cancer in the blood. The test works with existing laboratory equipment and has been clinically validated to perform better than current standard of care tests with more accuracy. 

The Company has just completed a clinical trial which confirmed the test’s high sensitivity and specificity in detecting biomarkers of cancer. The study evaluated 989 samples, 737 of which made up the final data set. ColoSTAT again outperformed the current faecal test in this latest study with 35% more accuracy. Previous to this, the Company had referenced a study figure of 33%. The current study also confirmed that ColoSTAT was more accurate at detecting advanced adenomas (precursor to cancer) than the standard of care test. 

CEO and Managing Director, Glenn Gilbert said: “We are extremely pleased with the significant positive outcomes from this study. It further supports our conviction that ColoSTAT has the potential to transform the way colorectal cancer is detected, on a global scale. 

“We express our gratitude to the patients and thank our partners for the work completed thus far, including our Clinical Research Organisation, Accelagen, our statisticians, Statistical Revelations, the individual trial sites and our analytical testing partner Sonic Clinical Trials (a 100% owned subsidiary of Sonic Healthcare ASX: SHL). 

“To achieve such a strong overall performance result and further, the meaningful clinical significance versus the current market standard, FIT, further strengthens Rhythm’s position for significant positive outcomes moving forward, both economically and socially.”

No doubt the study results bode well for Rhythm. The Company estimates the market opportunity for ColoSTAT and similar biomarker cancer detection tests to exceed USD $38 billion, with the potential to reach over 771 million people to screen for colorectal cancer. 

The Company is hoping to commercialise the test by late 2022. The test is already patented in multiple jurisdictions and has received the CE Mark for use in Europe. 

Keenly awaiting the chance to start generating sales, Rhythm rounded out the half year ended 31 December 2021 with $5.5 million in cash

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • accelagen
  • asx rhy
  • asx shl
  • colostat
  • rhthym biosciences
  • rhy
  • sonic healthcare
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.